Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Cigna

The $18,000 breast biopsy

The hospital estimated the biopsy would cost $1,400. How did it end up being so much more, even with insurance?

Salon

5 Dividend Stocks to Buy and Hold Forever

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

StockNews.com

Check Out What Whales Are Doing With Cigna

A whale with a lot of money to spend has taken a noticeably bearish stance on Cigna. Looking at options history for Cigna (NYSE:CI) we detected 15 strange trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The $18,000 breast biopsy: When having insurance costs you a bundle

When Dani Yuengling felt a lump in her right breast last summer, she tried to ignore it.

Tribune News Service

An $18,000 biopsy? Paying cash might have been cheaper than using her insurance

A hospital's cost calculator said her procedure would be $1,400 for patients without insurance. Instead, the bill was almost $18,000 and, her part was more than $5,000 — the balance of her deductible.

WEKU

What Are Whales Doing With Cigna

Someone with a lot of money to spend has taken a bearish stance on Cigna (NYSE:CI). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Looking At Cigna's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Cigna. Looking at options history for Cigna (NYSE:CI) we detected 13 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Looking At Cigna's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Cigna. Looking at options history for Cigna (NYSE:CI) we detected 11 strange trades.

Benzinga

Here's How Much You Would Have Made Owning Cigna Stock In The Last 10 Years

Cigna (NYSE:CI) has outperformed the market over the past 10 years by 9.15% on an annualized basis producing an average annual return of 20.13%. Currently, Cigna has a market capitalization of $84.90 billion.

Benzinga

Morgan Stanley Upgrades Cigna On Humira Prospects

Cigna Corp (NYSE: CI) is poised to benefit from the launch of bioequivalent Humira in July 2023, according to Morgan Stanley.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2022

Upgrades

Benzinga

3 Attractive 'Growth at a Reasonable Price' Stocks to Buy Now

GARP is a strategy to blend the best parts of value and growth investing. It's particularly apt as it will allow investors to identify the top growth stocks trading at attractive valuations such as Cigna (CI), Freeport McMoran (FCX), and Micron (MU).

StockNews.com

What 15 Analyst Ratings Have To Say About Cigna

Within the last quarter, Cigna (NYSE:CI) has observed the following analyst ratings:

Benzinga

Oz profits from insulin price gougers

Mehmet Oz specifically called out UnitedHealth and CVS for soaring prices — but he's heavily invested in both

Salon

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Attractive 'Growth at a Reasonable Price' Stocks to Buy Now

Growth stocks have been mired in a brutal bear market. However, a handful of stocks are quite cheap and continue to grow at an impressive rate. 3 such stocks that investors should consider buying are Cigna (CI), Micron (MU), and Freeport McMoran (FCX).

Tribune News Service

Federal regulators probe Cigna’s pharmacy benefit manager, CVS Caremark, and others. What are they investigating?

Express Scripts, the pharmacy benefit manager that Cigna Corp. bought in 2018, is being investigated by the Federal Trade Commission for what regulators claim is influence over drug prices wielded by pharmacy benefit managers and transparent business practices.

Benzinga

Analyzing Cigna's Short Interest

Cigna's (NYSE:CI) short percent of float has fallen 6.8% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 0.96% of all regular shares that are available for trading.

Benzinga

What Are Whales Doing With Cigna

Someone with a lot of money to spend has taken a bullish stance on Cigna (NYSE:CI). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

When medical test costs suddenly change

Preventive care should be free under the ACA. An investigation found it doesn't always work that way in practice

WEKU

Cancer screenings like colonoscopies are supposed to be free. Hers cost $2,185

Preventive care, like screening colonoscopies, is supposed to be free of charge to patients under the Affordable Care Act. But some hospitals haven't gotten the memo.

Benzinga

$1000 Invested In Cigna 10 Years Ago Would Be Worth This Much

Cigna (NYSE:CI) has outperformed the market over the past 10 years by 7.87% on an annualized basis producing an average annual return of 19.99%. Currently, Cigna has a market capitalization of $86.15 billion.

Benzinga

14 Analysts Have This to Say About Cigna

Cigna (NYSE:CI) has observed the following analyst ratings within the last quarter:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2022

Upgrades

Tribune News Service

Supreme Court leak prompts investors to press companies on abortion

WASHINGTON — Activist shareholders, seeking to galvanize support following a leaked Supreme Court draft opinion indicating that justices are poised to overturn Roe v. Wade, are pressing companies to explicitly explain how they will support their workers’ access to abortion and reproductive health services.

Roll Call

SCOTUS leak prompts investors to press companies on abortion - Roll Call

Activist shareholders are pressuring companies on access to abortion after a leaked draft Supreme Court opinion.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.